Up to $1,175


Lupus: LILAC Study

Official Title


Study Summary

The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of BIIB059 (Parts A and B).

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 18-75
Inclusion At least one sign off active skin disease, including acute, subacute, and/or chronic cutaneous lupus.
Exclusion Active lupus nephritis or moderate-to-severe or chronic kidney disease.
Start Date
Compensation Up to $1,175 USD
Location Orlando, FL

Study Information

Condition Lupus
Study Phase Phase 2

Administrative Information

Study ID NCT02847598
Investigators George Stoica, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.